STOCK TITAN

Traws Pharma (TRAW) awards 14,150 stock options to company director

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Traws Pharma, Inc. director Clarke Trafford received a grant of stock options to purchase 14,150 shares of common stock at an exercise price of $0.68 per share. The options were awarded under the company’s 2021 Incentive Compensation Plan, vest 100% one year after the grant date, and expire on July 9, 2036, leaving Trafford with 14,150 options following the award.

Positive

  • None.

Negative

  • None.
Insider Clarke Trafford
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy) 14,150 $0.00 --
Holdings After Transaction: Stock Option (right to buy) — 14,150 shares (Direct)
Footnotes (1)
  1. [object Object]
Stock options granted 14,150 options Grant of stock options to director Clarke Trafford on 2026-07-09
Exercise price $0.68 per share Exercise price of the granted stock options
Underlying shares 14,150 shares Each option is exercisable for one share of common stock
Total options after grant 14,150 options Total derivative securities held following this award
Exercise date 2027-07-09 Date from which the options are first exercisable after full vesting
Expiration date 2036-07-09 Final expiration date of the stock option award
Stock Option (right to buy) financial
"security_title: Stock Option (right to buy)"
2021 Incentive Compensation Plan financial
"awarded by the Issuer's compensation committee under the Issuer's 2021 Incentive Compensation Plan"
exercise price financial
"conversion_or_exercise_price: 0.6800"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-07-09"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

Who is the insider involved in this TRAW Form 4 transaction?

The insider is Clarke Trafford, a director of Traws Pharma, Inc. He reported receiving a grant of stock options as equity compensation from the company’s board compensation committee under the 2021 Incentive Compensation Plan.

What type of security did Clarke Trafford receive in the TRAW filing?

Clarke Trafford received a stock option (right to buy) award. Each option is exercisable for one share of Traws Pharma common stock, providing equity-based compensation rather than an immediate stock purchase in the open market.

How many stock options were granted to Clarke Trafford in TRAW?

Clarke Trafford was granted 14,150 stock options. Following this grant, his reported holdings of this option award total 14,150 derivative securities, all tied to an equivalent number of underlying shares of Traws Pharma common stock.

What is the exercise price of Clarke Trafford’s TRAW stock options?

The stock options carry an exercise price of $0.68 per share. This means Trafford can purchase Traws Pharma common stock at $0.68 per share upon exercise, subject to vesting and before the options’ expiration date.

When do Clarke Trafford’s TRAW stock options vest and expire?

The options vest 100% on the first anniversary of the July 9, 2026 grant date. They have an expiration date of July 9, 2036, giving a long window for potential exercise once fully vested.

Under which plan were the TRAW stock options to Clarke Trafford granted?

The options were granted under Traws Pharma’s 2021 Incentive Compensation Plan, as amended and/or restated. The award was approved by the company’s compensation committee, which is comprised of independent directors overseeing equity compensation.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Clarke Trafford

(Last)(First)(Middle)
C/O TRAWS PHARMA, INC.
12 PENNS TRAIL

(Street)
NEWTOWN PENNSYLVANIA 18940

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/09/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy)$0.6807/09/2026A14,15007/09/2027(1)07/09/2036Common Stock14,150$014,150D
Explanation of Responses:
1. Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.
/s/ Trafford Clarke07/14/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)